Weight loss pills you don't have to inject

The injection barrier is real. A large share of people who could benefit from GLP-1 medications won't consider them — not because of cost, not because of side effects, but because of the needle. That's a completely legitimate reason. A treatment you won't use isn't a treatment at all.

The good news is that 2026 changed the picture significantly. For most of the past decade, the pill options for weight loss were older drugs with modest results. That changed when oral semaglutide — the same active ingredient as the Wegovy injection — received FDA approval in December 2025. Then in April 2026, Foundayo (orforglipron) was approved: the world's first small-molecule GLP-1 pill, meaning it's not a peptide and has no dosing restrictions at all. Suddenly there are two modern GLP-1 pills competing with the injections that have dominated the conversation.

Alongside those two newer options, there are two older prescription pills that have quietly been available for years — generic Qsymia and Contrave — plus one over-the-counter option. In total, if needles are off the table, there are five options worth knowing about. Here's the trial data for each of them.

A note on the numbers: the percentages below are averages from clinical trials. Individual results vary considerably. The trials ran for different lengths of time under different conditions, so the numbers aren't perfectly apples-to-apples. What they do give you is a consistent sense of scale — how these options compare to each other and to the injections.

The two modern GLP-1 pills

The most important development in this space is that GLP-1 receptor agonists — the class of drug behind Ozempic, Wegovy, and Mounjaro — now come in pill form. Until recently, GLP-1 drugs were peptide molecules that broke down in the digestive system before they could be absorbed, which is why they had to be injected. Two different approaches have now solved that problem.

Oral Wegovy (semaglutide 25 mg) received FDA approval in December 2025. In the OASIS 4 trial — 307 participants over 64 weeks — participants lost an average of 13.6% of their body weight. That's roughly 30 lbs for a 220 lb person. Among participants with full medication adherence, the figure was 16.6%. It costs around $149 per month self-pay, or as little as $25 per month with insurance coverage. The active ingredient is identical to the Wegovy injection — the same drug, just delivered differently.

There is one meaningful catch with oral Wegovy: the dosing instructions are strict. It needs to be taken first thing in the morning on a completely empty stomach, with a small sip of water only — no more than 120 ml — and then you wait 30 minutes before eating or drinking anything else. This is because the peptide molecule needs very specific stomach conditions to absorb properly. For many people that's manageable. For others — shift workers, people with irregular mornings, anyone who exercises fasted — it becomes a genuine daily hassle.

Foundayo (orforglipron) was approved in April 2026 and takes a completely different approach. It's a small-molecule GLP-1 — not a peptide — which means it's chemically stable in the gut and absorbs regardless of when or what you eat. No fasting window, no water restriction, no timing requirements. You take it whenever works for you. In the ATTAIN-1 trial — 72 weeks with adults with obesity — participants lost an average of 12.4% of body weight. That's about 27 lbs for a 220 lb person. Cost is $149 to $349 per month via LillyDirect, the manufacturer's direct program.

The ATTAIN-MAINTAIN trial looked specifically at people who were already on injectable GLP-1 medications and switched to Foundayo. Their weight was maintained — the average difference after switching was less than 1 kg. That suggests for someone already doing well on an injection, a switch to the pill isn't a step down.

How do you choose between the two? The efficacy numbers are close enough that they're not the deciding factor — 13.6% versus 12.4% is a smaller gap than the trial methodologies can reliably distinguish. The real difference is the dosing rule. If you can build a consistent morning routine and the fasting window doesn't bother you, oral Wegovy may have slightly better insurance coverage given it's been on the market longer. If you want total freedom — take it with food, take it at night, skip the planning — Foundayo is the more convenient option. For most people, whichever one their insurance covers better is the right starting point.

The older proven pills

Before the GLP-1 pills arrived, the two main prescription pill options were generic Qsymia (phentermine-topiramate) and Contrave (naltrexone-bupropion). They work through completely different mechanisms from GLP-1 drugs, and that's worth understanding — because different mechanisms mean different side effect profiles and, for some people, better personal fit.

Generic Qsymia combines phentermine (a stimulant, in the same family as older diet pills) with topiramate (an anticonvulsant medication also used for migraines). In the CONQUER trial — 2,487 participants over 56 weeks, one of the larger weight-loss pill trials ever run — participants lost an average of 9.8% of body weight. That's about 22 lbs for a 220 lb person. The self-pay cost is around $30 to $80 per month for the generic version, making it far and away the cheapest effective option on this list. The side effects to watch for are tingling sensations in the hands and feet (about 20% of participants in trials) and dry mouth (about 21%). A smaller number of people report cognitive effects — difficulty with word-finding, slower processing — sometimes called "topamax fog" after the brand name for topiramate. It's not suitable during pregnancy.

Contrave combines naltrexone (used in addiction medicine to block opioid receptors) with bupropion (an antidepressant also marketed as Wellbutrin). This combination targets the brain's reward and craving pathways rather than appetite hormones — a different approach entirely. In the COR-I trial — 1,742 participants over 56 weeks — participants lost an average of 6.1% of body weight, roughly 13 lbs for a 220 lb person. That's more modest than the other options on this list. Cost is typically $100 to $400 per month self-pay depending on pharmacy and insurance. It's taken twice daily. Because it contains bupropion, it cannot be combined with opioid medications. For people where emotional eating, cravings, or the mood-food connection are central to the picture, the mechanism might be a particularly relevant fit — though that's a conversation to have with a prescriber.

Neither of these drugs produces outcomes as strong as the GLP-1 pills, but they have long track records, are affordable in generic form, and work through mechanisms that suit some people better. "Less powerful on average" and "right for this person" are not mutually exclusive.

The over-the-counter option

If you want to skip the prescriber visit entirely, Alli (orlistat 60 mg) is the only FDA-approved weight-loss pill available without a prescription. It works by blocking roughly a third of dietary fat from being absorbed — the unabsorbed fat passes through the digestive system instead. In clinical trials, participants lost an average of around 5 to 6% of body weight. The 4-year XENDOS study confirmed its long-term safety profile. Cost is around $40 to $60 per month at most pharmacies.

The trade-off for that accessibility is real. Because fat passes through unabsorbed, the GI side effects — loose stools, oily discharge, urgency — are common, especially on high-fat meals. Managing those effects means keeping dietary fat moderate, which requires planning. The results are also the most modest of any option here. It's not a bad tool, but it's a weak one compared to the prescription options. What it offers that nothing else does is this: no appointment, no waiting for insurance approval, available today. For some people, that accessibility is exactly what matters.

How these compare to injections

The best-performing injection in current trials is tirzepatide (Zepbound / Mounjaro), which produced average weight loss of 20.9% in the SURMOUNT-1 trial. The best pill — oral Wegovy — produced 13.6% to 16.6% depending on the trial population. That's a real gap. The pills are not equal to the injections on raw weight loss numbers.

But here's the part that matters more than the headline numbers: a treatment you actually take beats a treatment you don't take. Medication adherence data consistently shows that people who have strong psychological barriers to injections take them less consistently — they delay starting, skip doses under stress, or stop at the first sign of difficulty. A 13.6% average from a pill you take every day will outperform a 20.9% average from an injection you find excuses to skip or never start. This is not rationalisation; it's basic behavioural reality.

The ATTAIN-MAINTAIN trial data reinforces this from another angle. People who were already doing well on injectable GLP-1 medications and switched to Foundayo maintained their weight. The pill held what the injection built. That suggests the pill isn't a compromise position — it's a legitimate long-term maintenance path, not just a starter option.

All five options at a glance

Here's how the five options sit next to each other. Weight loss figures are averages from the primary clinical trials referenced above — individual results vary.